Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
Revenue
Gilead Sciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Moderna Inc
NASDAQ:MRNA
|
Revenue
$6.8B
|
CAGR 3-Years
104%
|
CAGR 5-Years
119%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Gilead Sciences Inc
Revenue Breakdown
Breakdown by Geography
Gilead Sciences Inc
Total Revenue:
27.1B
USD
|
United States:
19.4B
USD
|
Europe:
4.3B
USD
|
Other International:
3.4B
USD
|
Breakdown by Segments
Gilead Sciences Inc
Total Revenue:
27.1B
USD
|
Products, Other Hiv:
18.2B
USD
|
Cell Therapy Products, Total Cell Therapy Pro...:
2.2B
USD
|
Veklury:
2.2B
USD
|
Trodelvy:
1.1B
USD
|
Hepatitis B Virus / Hepatitis Delta Virus Pro...:
1B
USD
|
Other Products, Total Other Product Sales:
859m
USD
|
See Also
What is Gilead Sciences Inc's Revenue?
Revenue
27.1B
USD
Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Revenue amounts to 27.1B USD.
What is Gilead Sciences Inc's Revenue growth rate?
Revenue CAGR 10Y
9%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Gilead Sciences Inc have been 3% over the past three years , 4% over the past five years , and 9% over the past ten years .